JAPAN’S UA Zensen, a labour union group representing retail, restaurant and other industry unions, said on Wednesday that its ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

1 (tie), Lauren Coughlin and Rio Takeda, 3. 3, 9 tied with 2. 1 (tie), Jaravee Boonchant, In Gee Chun, Jessica Porvasnik, Julia Lopez Ramirez, Miranda Wang and Fiona Xu, 1.00%. 7, Andrea Lee, .88%. 8, ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

Plus: Maura Healey meets with eds-and-meds leaders about threats to research funding; Takeda sends zebras flying at Celtics ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Protein S is a key vitamin K-dependent plasma protein involved in the regulation of coagulation. Deficiency of protein S, ...

These socks, by Maria La Rosa, look like foil balloons, make a crackling sound when slipped on and, for some people, have ...

Emerging tools enable more accurate antigen production and presentation using mRNA instead of protein. In recent years, mRNA technology has come into its own, most prominently in the field of vaccine ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...